Key facts
- Fermelanta’s last known valuation is $30.5M (Aug 2025).
- It has raised $15.0M; the latest was Early Stage VC ($13.6M) in Aug 2025.
- Notable investors include Plug and Play Tech Center, Mitsubishi UFJ Capital, Japan External Trade Organization, Beyond Next Ventures, QR Investment — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Fermelanta
- ·The full record, as it builds
Funding rounds
No funding rounds for Fermelanta are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fermelanta
Operator of a biotechnology company intended to make beneficial plant-based chemicals by microorganisms. The company develops plant secondary metabolites using a microbial fermentation process for industrial raw materials and ingredients including medicines, cosmetics, or supplements and contributes to the health of humans and the planet, enabling companies with sustainable and environment-friendly chemicals.
- Sector
- Healthcare
- HQ
- Nonoichi, Japan
- Founded
- 2022
- Employees
- 12
- Website
- fermelanta.com/
- Ownership
- Privately Held (backing)
Fermelanta doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fermelanta shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fermelanta in its N-PORT filings yet. We sweep new filings monthly.